Calcipotriol Sandoz 0.05 mg/g voide Suomi - suomi - Fimea (Suomen lääkevirasto)

calcipotriol sandoz 0.05 mg/g voide

sandoz a/s - calcipotriol - voide - 0.05 mg/g - kalsipotrioli

Coagadex Euroopan unioni - suomi - EMA (European Medicines Agency)

coagadex

bpl bioproducts laboratory gmbh - ihmisen hyytymistekijä x - faktorin x puute - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex on tarkoitettu verenvuototapahtumien hoitoon ja ennaltaehkäisyyn sekä perioperatiiviseen hoitoon potilailla, joilla on perinnöllinen tekijä x-puutos. coagadex on tarkoitettu kaikille ikäryhmille.

Bio-E-Vitamin 350 mg kapseli, pehmeä Suomi - suomi - Fimea (Suomen lääkevirasto)

bio-e-vitamin 350 mg kapseli, pehmeä

pharma nord aps - dextro alpha-tocopherol - kapseli, pehmeä - 350 mg - tokoferoli (e-vitamiini)

C-VITAMIN 500 500 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

c-vitamin 500 500 mg tabletti

schering oy - happo ascorbicum - tabletti - 500 mg - askorbiinihappo (c-vitamiini)

B-VITAMIN COMP tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

b-vitamin comp tabletti

medica - kalsium pantothenas,riboflavinum,thiamini hydrochloridum,nicotinamidum,pyridoxini hydrochloridum - tabletti - b-vitamiinien yhdistelmävalmisteet

B-VITAMIN COMP injektioneste Suomi - suomi - Fimea (Suomen lääkevirasto)

b-vitamin comp injektioneste

medica - riboflavini natrii phosphas,thiamini hydrochloridum,pyridoxini hydrochloridum,nicotinamidum,dexpanthenolum - injektioneste - b-vitamiinien yhdistelmävalmisteet

C-VITAMIN 500 500 mg purutabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

c-vitamin 500 500 mg purutabletti

schering oy - natrii ascorbas,happo ascorbicum - purutabletti - 500 mg - askorbiinihappo (c-vitamiini)

VITAMIN E 100 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

vitamin e 100 mg tabletti

nycomed oy - oikea-alfa-tocopheroli acetas - tabletti - 100 mg - tokoferoli (e-vitamiini)

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.